News & Media

Press release Regulatory
New data for simeprevir will be presented at EASL's International Liver Congress 2016

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new clinical data for simeprevir, an NS3 / 4A protease...

Read more
Press release Regulatory
Annual Report 2015

- Medivir continued to build long-term value in 2015 via a R&D portfolio based on our established and proven technology platform....

Read more
Press release Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders in Medivir AB are hereby summoned to the annual general meeting on Tuesday 3 May 2016 at 2 p.m....

Read more
Press release Regulatory
Medivir’s Nomination Committee proposes new Board of Directors ahead of 2016 AGM

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced the Nomination Committee’s proposal for a new Board of Directors that...

Read more
Press release Regulatory
MEDIVIR AB – FINANCIAL STATEMENT, JANUARY – DECEMBER 2015

Financial summary Fourth quarter 2015 (2014) Net turnover totalled SEK 84.7 million (377.0 m), SEK 31.1 million (220.1 m) of which...

Read more
Press release Regulatory
Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces the enrolment of the first patient into a randomized double-blind phase...

Read more
Press release Regulatory
OLYSIO® sales during the fourth quarter 2015

The royalty for the fourth quarter amounted to 31 MSEK (3.4 MEUR). Medivir’s royalties based on sales for the fourth quarter...

Read more